These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 37819154)

  • 1. Immunotherapy for myelodysplastic syndrome and acute myeloid leukemia: where do we stand?
    Spillane DR; Assouline S
    Expert Rev Hematol; 2023; 16(11):819-834. PubMed ID: 37819154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BITES and CARS and checkpoints, oh my! Updates regarding immunotherapy for myeloid malignancies from the 2018 annual ASH meeting.
    Przespolewski AC; Griffiths EA
    Blood Rev; 2020 Sep; 43():100654. PubMed ID: 32029263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice.
    Masarova L; Kantarjian H; Ravandi F; Sharma P; Garcia-Manero G; Daver N
    Adv Exp Med Biol; 2018; 995():97-116. PubMed ID: 30539507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
    Liu Y; Bewersdorf JP; Stahl M; Zeidan AM
    Blood Rev; 2019 Mar; 34():67-83. PubMed ID: 30553527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel immune directed therapies in myelodysplastic syndromes and acute myeloid leukemia.
    Brunner AM
    Curr Opin Hematol; 2023 Mar; 30(2):38-44. PubMed ID: 36728945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
    Masarova L; Kantarjian H; Garcia-Mannero G; Ravandi F; Sharma P; Daver N
    Adv Exp Med Biol; 2017; 995():73-95. PubMed ID: 28321813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome.
    Arellano-Ballestero H; Sabry M; Lowdell MW
    Cells; 2023 Feb; 12(4):. PubMed ID: 36831300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint Inhibitors and Other Immune-Based Therapies in Acute Myeloid Leukemia.
    Haddad F; Zeidan AM; Daver N
    Cancer J; 2022 Jan-Feb 01; 28(1):43-50. PubMed ID: 35072373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Immunotherapy for Acute Myeloid Leukemia.
    Tabata R; Chi S; Yuda J; Minami Y
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Gallazzi M; Ucciero MAM; Faraci DG; Mahmoud AM; Al Essa W; Gaidano G; Mouhssine S; Crisà E
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia.
    Kapoor S; Champion G; Basu A; Mariampillai A; Olnes MJ
    Cancers (Basel); 2021 Oct; 13(19):. PubMed ID: 34638510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.
    Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE
    Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging role of immune checkpoint based approaches in AML and MDS.
    Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
    Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer cell (NK) subsets and NK-like T-cell populations in acute myeloid leukemias and myelodysplastic syndromes.
    Aggarwal N; Swerdlow SH; TenEyck SP; Boyiadzis M; Felgar RE
    Cytometry B Clin Cytom; 2016 Jul; 90(4):349-57. PubMed ID: 26648320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute myeloid leukemia and myelodysplastic syndrome associated with a combination of immune checkpoint inhibitor and platinum-based chemotherapy.
    Nakatsuru K; Tsubouchi K; Hirahata M; Nakashima T; Takahata Y; Okamatsu Y; Shiraishi Y; Okamoto I; Harada T
    Thorac Cancer; 2023 Aug; 14(22):2225-2228. PubMed ID: 37337950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Abaza Y; Zeidan AM
    Cells; 2022 Jul; 11(14):. PubMed ID: 35883692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelodysplastic syndrome and immunotherapy novel to next in-line treatments.
    Linder K; Lulla P
    Hum Vaccin Immunother; 2021 Aug; 17(8):2602-2616. PubMed ID: 33941042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.
    Hattori N; Nakamaki T
    Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Finding potential targets in cell-based immunotherapy for handling the challenges of acute myeloid leukemia.
    Kheirkhah AH; Habibi S; Yousefi MH; Mehri S; Ma B; Saleh M; Kavianpour M
    Front Immunol; 2024; 15():1460437. PubMed ID: 39411712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.
    Zhao A; Zhao M; Qian W; Liang A; Li P; Liu H
    Front Immunol; 2022; 13():1063986. PubMed ID: 36713414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.